Ranbaxy Issues Allergy Drug Recall From Its Sole U.S.-Approved Plant
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories said it has ordered a recall of a batch of its loratadine generic allergy drug made at its only plant allowed to supply drugs in the U.S., its Ohms Laboratories unit.